KEYNOTE-695 study: Tavo + Keytruda demonstrate 30% ORR in anti-PD-1 checkpoint refractory metastatic melanoma

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

In a phase IIb study, Tavo (tavokinogene telseplasmid) in combination with Keytruda (pembrolizumab) led to a 30% overall response rate in the first 54 out of 100 planned patients who have rigorously defined anti-PD1 checkpoint resistant metastatic melanoma.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

I was really excited to get to talk about the role that mentorship plays in women’s leadership development. It’s a topic that I’ve thought a lot about, and also that I’ve benefitted from, and that I think is not always applied with enough intention. There is an art to mentorship, and I want to share some of how that has helped me navigate career transitions and pivot to leadership roles.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login